Search research articles
Contact Us
Filters
Showing results (11-20 of 110) with videos related to
Page
of 11
Sort By:
Health Affairs (Project Hope)
|
September 13, 2006
An evaluation of Oregon's evidence-based Practitioner-Managed Prescription Drug Plan
Daniel M Hartung, Kathy L Ketchum, Dean G Haxby
Neurology. Clinical Practice
|
April 23, 2016
Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
Dennis N Bourdette, Daniel M Hartung, Ruth H Whitham
Neurology
|
February 12, 2016
Author response
Daniel M Hartung, Dennis N Bourdette, Ruth H Whitham
Neurology
|
February 12, 2016
Author response
Daniel M Hartung, Dennis N Bourdette, Ruth H Whitham
Obstetrics and Gynecology
|
May 29, 2019
Pharmacist Provision of Hormonal Contraception in the Oregon Medicaid Population
Lorinda Anderson, Daniel M Hartung, Luke Middleton, et al.
Substance Abuse
|
December 20, 2015
A chronic opioid therapy dose reduction policy in primary care
Melissa B Weimer, Daniel M Hartung, Sharia Ahmed, et al.
Diabetes Care
|
February 12, 2020
Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
Chien-Wen Tseng, Camlyn Masuda, Randi Chen, et al.
Journal of the American Board of Family Medicine : JABFM
|
May 10, 2013
Breaking up is hard to do: lessons learned from a pharma-free practice transformation
David Evans, Daniel M Hartung, Denise Beasley, et al.
CNS Drugs
|
June 27, 2012
Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study
Daniel M Hartung, Luke Middleton, Leanne Svoboda, et al.
Neurology
|
February 12, 2016
Author response
Daniel M Hartung, Dennis N Bourdette, Sharia Ahmed, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 110) with videos related to
Sort By:
Page
of 11
Health Affairs (Project Hope)
|
September 13, 2006
An evaluation of Oregon's evidence-based Practitioner-Managed Prescription Drug Plan
Daniel M Hartung, Kathy L Ketchum, Dean G Haxby
Neurology. Clinical Practice
|
April 23, 2016
Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
Dennis N Bourdette, Daniel M Hartung, Ruth H Whitham
Neurology
|
February 12, 2016
Author response
Daniel M Hartung, Dennis N Bourdette, Ruth H Whitham
Neurology
|
February 12, 2016
Author response
Daniel M Hartung, Dennis N Bourdette, Ruth H Whitham
Obstetrics and Gynecology
|
May 29, 2019
Pharmacist Provision of Hormonal Contraception in the Oregon Medicaid Population
Lorinda Anderson, Daniel M Hartung, Luke Middleton, et al.
Substance Abuse
|
December 20, 2015
A chronic opioid therapy dose reduction policy in primary care
Melissa B Weimer, Daniel M Hartung, Sharia Ahmed, et al.
Diabetes Care
|
February 12, 2020
Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
Chien-Wen Tseng, Camlyn Masuda, Randi Chen, et al.
Journal of the American Board of Family Medicine : JABFM
|
May 10, 2013
Breaking up is hard to do: lessons learned from a pharma-free practice transformation
David Evans, Daniel M Hartung, Denise Beasley, et al.
CNS Drugs
|
June 27, 2012
Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study
Daniel M Hartung, Luke Middleton, Leanne Svoboda, et al.
Neurology
|
February 12, 2016
Author response
Daniel M Hartung, Dennis N Bourdette, Sharia Ahmed, et al.
Page
of 11